Results of the PERFORM magnetic resonance imaging study.

Details

Serval ID
serval:BIB_56D81A4101DB
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Results of the PERFORM magnetic resonance imaging study.
Journal
Journal of Neurology
Author(s)
Chabriat H., Maeder P., Gass A., Michel P., Bracoud L., Hennerici M.
ISSN
1432-1459 (Electronic)
ISSN-L
0340-5354
Publication state
Published
Issued date
2013
Volume
260
Number
12
Pages
3071-3076
Language
english
Notes
Publication types: Journal ArticlePublication Status: ppublish. PDF type: ORIGINAL COMMUNICATION
Abstract
The PERFORM MRI Project was an ancillary study of the PERFORM trial. Its aim was to investigate the potential effects of terutroban in patients with atherothrombotic disorders, in comparison to aspirin, on the evolution of magnetic resonance imaging (MRI) lesions after a recent ischemic stroke or transient ischemic attack (TIA). The change in both hypointense and hyperintense lesions on the fluid attenuated inversion recovery (FLAIR) sequence, in the total brain volume and in the hippocampal volume from baseline (M1) to the final visit (M24) was assessed as well as the number of emergent microbleeds. A total of 748 patients had their MRI examination validated both at M1 and M24 during the study. At baseline, the volume of hypointense and hyperintense lesions on FLAIR images, the total brain volume, the hippocampal volume and the number of patients with microbleeds did not differ between the two groups. During follow-up, the mean volumetric increase of lesions hypointense or hyperintense on FLAIR images (from 5 to 8 %), the mean reduction of total brain volume (−0.4 %) and of hippocampal volume (−4 %), did not differ between the two treatment arms. The same parameters analysed ipsilateral to the ischaemic lesion did not differ either between the two groups. In the terutroban group, 16.3 % of patients presented with emergent microbleeds, 10.7 % in the aspirin group; this difference was not significant. In the PERFORM study, the progression of FLAIR lesions, of cerebral or hippocampal atrophy and of microbleeds did not differ between patients treated by terutroban and those treated by aspirin.
Pubmed
Web of science
Create date
03/01/2014 10:29
Last modification date
20/08/2019 15:11
Usage data